This recommendation was based on the unique pharmacokinetics in Japanese subjects showing higher rivaroxaban exposure than Caucasian subjects when using the same dosage [4], and the Japanese Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (J-ROCKET AF) proved the safety and efficacy of this low-dose rivaroxaban medication in Japanese NVAF patients [5]. The gene discussed is F10; the disease is Stroke.